. 2023 Feb 20;24(4):4188. doi: 10.3390/ijms24044188

Table 1.

α₁-Adrenergic Receptor Agonists and Antagonists.

Drug	Receptor Selectivity	Current Indications	Potential Indications
Agonists
Non-selective
Norepinephrine	α₁ = α₂ = β	Septic and refractory
Epinephrine	α₁ = α₂ = β	shock, Cardiopulmonary arrest
		Hypotension
Selective
Phenylephrine	α₁ > α₂ >> β	Pupil dilation, Rosacea
Oxymetazoline	α_1A > α_1D = α_1B	Nasal decongestion, Rosacea
Methoxamine	α_1A > α_1D > α_1B	Septic and refractory shock
Cirazoline	α_1A > α_1D > α_1B		HF, Ischemia, cataracts
A-61603	α_1A > α_1D = α_1B		HF, Ischemia, cataracts
Dabuzalgron	α_1A >> α_1D = α_1B		HF, Ischemia, cataracts
Cmpd-3 ¹	α_1A >> α_1D > α_1B		AD, HF, Ischemia, cataracts
Antagonists
Non-selective
Prazosin	α_1A = α_1D = α_1B	BPH, Therapy-resistant	COVID-19/SARS, PD,
Doxazosin	α_1A = α_1D = α_1B	Hypertension,	ALS, PTSD,
Terazosin	α_1A = α_1D = α_1B	Pheochromocytoma	Hyperinflammation
Alfuzosin	α_1A = α_1D = α_1B
Selective
BMY7378	α_1D > α_1A >> α_1B
Tamsulosin	α_1A = α_1D > α_1B	BPH, Pheochromocytoma
Silodosin	α_1A > α_1D >> α_1B	BPH
5-Methylurapidil	α_1A > α_1D > α_1B
WB4101	α_1A = α_1D > α_1B

¹ [12]. AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; BPH, benign prostatic hyperplasia; HF, heart failure; PD, Parkinson’s disease; PTSD, posttraumatic stress disorder; SARS, severe acute syndrome coronavirus 2.